Paper498155
Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
Rossof AH and 7 others. Cancer Treat Rep, 1979. Cited by 82 papers, by iCite.
Cite this record
ConductScience Library. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Papers, record 498155. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498155
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Genital Neoplasms, Female | Major topic |
| Urogenital Neoplasms | Major topic |
| Digestive System | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Kidney | |
| Male | |
| Remission, Spontaneous |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 82 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 37996508 | Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. | Sci Rep | 2023 | https://conductscience.org/library/papers/37996508 | PubMed |
| 32668516 | Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options. | Korean J Intern Med | 2020 | https://conductscience.org/library/papers/32668516 | PubMed |
| 32160916 | Systematic analysis of ovarian cancer platinum-resistance mechanisms via text mining. | J Ovarian Res | 2020 | https://conductscience.org/library/papers/32160916 | PubMed |
| 30669514 | Platinum Resistance in Ovarian Cancer: Role of DNA Repair. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/30669514 | PubMed |
| 29255528 | Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. | J Rural Med | 2017 | https://conductscience.org/library/papers/29255528 | PubMed |
| 28060758 | Exosomes as mediators of platinum resistance in ovarian cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28060758 | PubMed |
| 26463832 | Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. | Cancer Discov | 2015 | https://conductscience.org/library/papers/26463832 | PubMed |
| 26308952 | Conditional Survival in de novo Metastatic Urothelial Carcinoma. | PLoS One | 2015 | https://conductscience.org/library/papers/26308952 | PubMed |
| 25429526 | Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17). | Br J Cancer | 2015 | https://conductscience.org/library/papers/25429526 | PubMed |
| 24722472 | CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. | PLoS One | 2014 | https://conductscience.org/library/papers/24722472 | PubMed |
| 24624361 | Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. | Front Oncol | 2014 | https://conductscience.org/library/papers/24624361 | PubMed |
| 21789133 | Practical considerations in ovarian cancer chemotherapy. | Ther Adv Med Oncol | 2010 | https://conductscience.org/library/papers/21789133 | PubMed |
| 17712400 | Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression? | Cancer Ther | 2007 | https://conductscience.org/library/papers/17712400 | PubMed |
| 16683074 | A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. | Invest New Drugs | 2006 | https://conductscience.org/library/papers/16683074 | PubMed |
| 15528984 | Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC). | Invest New Drugs | 2005 | https://conductscience.org/library/papers/15528984 | PubMed |
| 7149776 | Chemotherapy for advanced recurrent carcinoma of the cervix. A report on the treatment of 22 patients. | Arch Gynecol | 1982 | https://conductscience.org/library/papers/7149776 | PubMed |
| 6371015 | Developing new drugs for ovarian cancer: a challenging task in a changing reality. | J Cancer Res Clin Oncol | 1984 | https://conductscience.org/library/papers/6371015 | PubMed |
| 6357518 | Chemotherapy of advanced transitional cell carcinoma of the uroepithelium. | Cancer Chemother Pharmacol | 1983 | https://conductscience.org/library/papers/6357518 | PubMed |
| 3909096 | Cisplatin: a review of clinical applications and renal toxicity. | Pharm Weekbl Sci | 1985 | https://conductscience.org/library/papers/3909096 | PubMed |
| 3192385 | Phase I--preliminary phase II trial of iproplatin, a cisplatin analogue. | Invest New Drugs | 1988 | https://conductscience.org/library/papers/3192385 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/498155
GET https://conductscience.org/api/papers/v1/498155/cited_by?page=2